Novo to continue Patent suit, Pfizer wins first round!

Novo Nordisk will continue fighting patent suit against Pfizer over the inhaler insulin product Exubera following adverse decision of a U.S. district judge to dismiss a preliminary motion against Pfizer. Judge Leonard Sand in his judgment denied to immediately block sales of Pfizer’s Exubera product, saying the public’s need for a ‘new and less invasive treatment for diabetes’ outweighed Novo Nordisk’s claims that Pfizer is infringing on its patents. In his 13-page ruling, Sand said determination of the validity and infringement of these patents “will be well served through closer inspection at trial.”